Pharma Focus Asia

Takeda and IDT Collaborate on Johnson & Johnson COVID-19 Vaccine Manufacturing

Tuesday, March 16, 2021

Takeda Pharmaceutical Company Limited has just announced a mutual agreement with IDT Biologika GmbH ("IDT"), a development organization and contract manufacturing, to utilize previously reserved IDT capacity for Takeda's Dengue Vaccine Candidate (TAK-003). This capacity will be used to manufacture the single-dose COVID-19 vaccine developed by Johnson & Johnson's Janssen Pharmaceutical Companies. At the end of a three-month period, Takeda will regain this ability to resume critical manufacturing for the planned launch of its dengue vaccine, all subject to regulatory approvals.

"We are pleased to be working with IDT to contribute to Janssen's efforts to make its COVID-19 vaccine available and accessible to as many people as possible around the world," said Rajeev Venkayya, President, Global Business Unit. Takeda Vaccine. "We also recognize the huge unmet need for a dengue vaccine and will work closely with IDT to keep the impact on the supply of TAK-003 as low as possible."

“I appreciate the flexibility that Takeda, our long-time customer, has shown. This enables us to help supply the world with much-needed COVID-19 vaccines, "said Jürgen Betzing, CEO of IDT Biologika. “In recent months it has become very clear that the challenges posed by the pandemic can only be solved through collaboration and commitment. I believe that this conjunctural agreement between three industrial organizations demonstrates the will and capacity of our sector to contribute to solving this crisis in a creative way. With our production for Janssen and AstraZeneca, plus the development of our own vaccine against COVID-19 in collaboration with the German Center for Vaccine Research, DZIF, we can as a company make an important contribution to the fight against this disease. "

Through this agreement, Takeda now supports global access to three different COVID-19 vaccines. Earlier, Takeda announced its commitment to provide rapid and sustained access to COVID-19 vaccines in Japan through partnerships with Novavax and Moderna . Takeda will receive a manufacturing technology transfer from Novavax and will be responsible for development and commercialization, with a manufacturing capacity of more than 250 million doses. The company will also import and distribute 50 million doses of Moderna's COVID-19 mRNA vaccine as part of a joint partnership with Moderna and Japan's Ministry of Health, Labor and Welfare (MHLW). .

Takeda is in an excellent position to meet its commitments to support the public health needs associated with both COVID-19 and dengue. Takeda works with regulatory authorities and referral agencies, as appropriate, to reach out to eligible dengue vaccine candidates living in or traveling to communities affected by the dengue threat. More than half of the world's population is at risk of contracting dengue, and that number is expected to increase in the coming decades due to population growth, globalization, and urbanization.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024